133 related articles for article (PubMed ID: 36744580)
1. Editorial for "Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer".
Geitung JT
J Magn Reson Imaging; 2023 Nov; 58(5):1615-1616. PubMed ID: 36744580
[No Abstract] [Full Text] [Related]
2. Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer.
Bian X; Du S; Yue Z; Gao S; Zhao R; Huang G; Guo L; Peng C; Zhang L
J Magn Reson Imaging; 2023 Nov; 58(5):1603-1614. PubMed ID: 36763035
[TBL] [Abstract][Full Text] [Related]
3. Radiomics Signatures Based on Multiparametric MRI for the Preoperative Prediction of the HER2 Status of Patients with Breast Cancer.
Zhou J; Tan H; Li W; Liu Z; Wu Y; Bai Y; Fu F; Jia X; Feng A; Liu H; Wang M
Acad Radiol; 2021 Oct; 28(10):1352-1360. PubMed ID: 32709582
[TBL] [Abstract][Full Text] [Related]
4. Radiomic Signatures Derived from Diffusion-Weighted Imaging for the Assessment of Breast Cancer Receptor Status and Molecular Subtypes.
Leithner D; Bernard-Davila B; Martinez DF; Horvat JV; Jochelson MS; Marino MA; Avendano D; Ochoa-Albiztegui RE; Sutton EJ; Morris EA; Thakur SB; Pinker K
Mol Imaging Biol; 2020 Apr; 22(2):453-461. PubMed ID: 31209778
[TBL] [Abstract][Full Text] [Related]
5. Dynamic Contrast-Enhanced MRI Evaluation of Pathologic Complete Response in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After HER2-Targeted Therapy.
Heacock L; Lewin A; Ayoola A; Moccaldi M; Babb JS; Kim SG; Moy L
Acad Radiol; 2020 May; 27(5):e87-e93. PubMed ID: 31444111
[TBL] [Abstract][Full Text] [Related]
6. Expanding applications of MRI-based radiomics in HER2-positive breast cancer.
Park VY
EBioMedicine; 2020 Nov; 61():103085. PubMed ID: 33096473
[No Abstract] [Full Text] [Related]
7. Radiogenomic analysis of prediction HER2 status in breast cancer by linking ultrasound radiomic feature module with biological functions.
Cui H; Sun Y; Zhao D; Zhang X; Kong H; Hu N; Wang P; Zuo X; Fan W; Yao Y; Fu B; Tian J; Wu M; Gao Y; Ning S; Zhang L
J Transl Med; 2023 Jan; 21(1):44. PubMed ID: 36694240
[TBL] [Abstract][Full Text] [Related]
8. Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer.
Braman N; Prasanna P; Whitney J; Singh S; Beig N; Etesami M; Bates DDB; Gallagher K; Bloch BN; Vulchi M; Turk P; Bera K; Abraham J; Sikov WM; Somlo G; Harris LN; Gilmore H; Plecha D; Varadan V; Madabhushi A
JAMA Netw Open; 2019 Apr; 2(4):e192561. PubMed ID: 31002322
[TBL] [Abstract][Full Text] [Related]
9. Long-term Survival in Breast Cancer Patients Is Associated with Contralateral Parenchymal Enhancement at MRI: Outcomes of the SELECT Study.
Ragusi MAA; van der Velden BHM; Meeuwis C; Tetteroo E; Coerkamp EG; van Nijnatten TJA; Jansen FH; Wolters-van der Ben EJM; Jongen L; van Raamt F; Dorrius MD; Verloop J; Viergever MA; Pijnappel RM; Elias SG; Gilhuijs KGA
Radiology; 2023 May; 307(4):e221922. PubMed ID: 36975820
[TBL] [Abstract][Full Text] [Related]
10. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
[TBL] [Abstract][Full Text] [Related]
11. MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study.
Song SE; Bae MS; Chang JM; Cho N; Ryu HS; Moon WK
Acta Radiol; 2017 Jul; 58(7):792-799. PubMed ID: 27754920
[TBL] [Abstract][Full Text] [Related]
12. Value of radiomics based on CE-MRI for predicting the efficacy of neoadjuvant chemotherapy in invasive breast cancer.
Li Q; Huang Y; Xiao Q; Duan S; Wang S; Li J; Niu Q; Gu Y
Br J Radiol; 2022 Oct; 95(1139):20220186. PubMed ID: 36005646
[TBL] [Abstract][Full Text] [Related]
13. MRI-based radiogenomics analysis for predicting genetic alterations in oncogenic signalling pathways in invasive breast carcinoma.
Lin P; Liu WK; Li X; Wan D; Qin H; Li Q; Chen G; He Y; Yang H
Clin Radiol; 2020 Jul; 75(7):561.e1-561.e11. PubMed ID: 32183997
[TBL] [Abstract][Full Text] [Related]
14. Contrast-Enhanced Mammography and Radiomics Analysis for Noninvasive Breast Cancer Characterization: Initial Results.
Marino MA; Pinker K; Leithner D; Sung J; Avendano D; Morris EA; Jochelson M
Mol Imaging Biol; 2020 Jun; 22(3):780-787. PubMed ID: 31463822
[TBL] [Abstract][Full Text] [Related]
15. Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 PET Imaging: Challenges and Opportunities.
Ducharme M; Mansur A; Sligh L; Ulaner GA; Lapi SE; Sorace AG
PET Clin; 2023 Oct; 18(4):543-555. PubMed ID: 37339919
[TBL] [Abstract][Full Text] [Related]
16. An MRI-based Radiomics Classifier for Preoperative Prediction of Ki-67 Status in Breast Cancer.
Liang C; Cheng Z; Huang Y; He L; Chen X; Ma Z; Huang X; Liang C; Liu Z
Acad Radiol; 2018 Sep; 25(9):1111-1117. PubMed ID: 29428211
[TBL] [Abstract][Full Text] [Related]
17. MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer.
Bitencourt AGV; Gibbs P; Rossi Saccarelli C; Daimiel I; Lo Gullo R; Fox MJ; Thakur S; Pinker K; Morris EA; Morrow M; Jochelson MS
EBioMedicine; 2020 Nov; 61():103042. PubMed ID: 33039708
[TBL] [Abstract][Full Text] [Related]
18. Radiological predictive factors on preoperative multimodality imaging are related to Oncotype DX recurrence score in estrogen-positive/human epidermal growth factor receptor 2-negative invasive breast cancer: a cross-sectional study.
Tsukada H; Tsukada J; Ochi T; Noguchi E; Okamoto T
Ann Nucl Med; 2022 Oct; 36(10):853-864. PubMed ID: 35819628
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of ER, PR, FR and HER-2-Targeted Molecular Probes for Magnetic Resonance Imaging in Patients with Breast Cancer.
Jin YH; Hua QF; Zheng JJ; Ma XH; Chen TX; Zhang S; Chen B; Dai Q; Zhang XH
Cell Physiol Biochem; 2018; 49(1):271-281. PubMed ID: 30138940
[TBL] [Abstract][Full Text] [Related]
20. HER2-Positive Breast Cancer: Association of MRI and Clinicopathologic Features With Tumor-Infiltrating Lymphocytes.
Lee HJ; Lee JE; Jeong WG; Ki SY; Park MH; Lee JS; Nah YK; Lim HS
AJR Am J Roentgenol; 2022 Feb; 218(2):258-269. PubMed ID: 34431365
[No Abstract] [Full Text] [Related]
[Next] [New Search]
